About Jeanny Aragon-Ching, MD
Jeanny B. Aragon-Ching, MD, FACP, serves as the Clinical Program Director of Genitourinary Cancers at the Inova Schar Cancer Institute with a joint academic appointment as Associate Professor of Medical Education at the University of Virginia.
Dr. Aragon-Ching joined Inova Schar Cancer Institute in 2015 to spearhead the GU Oncology program and bring together multidisciplinary expertise and advancement of research, clinical trial development, and personalized clinical care of patients with GU cancers. She has since served in the ASCO GU Program Planning Committee from 2017-2019, served as Track Chair for Urothelial cancers in 2018 and Renal Cell Cancer Track in 2016–2017 and member of the Prostate cancer track. She has chaired different sessions on bladder urothelial and non-urothelial cancers, kidney and prostate cancers. She also served in the ASCO Cancer Education Committee for the annual meeting for the GU non-prostate cancers. She is dedicated to the research and clinical care of patients with genitourinary cancers.
Dr. Aragon-Ching completed her internship and residency at the Albert Einstein Medical Center in Philadelphia, PA, where she served the final year as Chief Resident. She later completed a Medical Oncology Fellowship at the National Cancer Institute, National Institutes of Health, in Bethesda, MD, where she served as an Associate Investigator on varying trials involved with pharmacogenomics and early drug discovery for genitourinary tumors. Dr. Aragon-Ching later moved to the George Washington University Medical Center in 2008 and was promoted to the rank of Associate Professor of Medicine in 2014.
Her early research work focused on the use of angiogenesis inhibitors, bone-targeted agents, circulating tumor cells, clinical trial design and drug development. She has served in varying capacities as a peer reviewer, editorial board member and expert panel for highly acclaimed journals and congressionally directed research program grants. She is a well-published author and investigator of multiple GU trials, including prostate cancer, bladder cancer and kidney cancer trials. She is a well-established educator and serves on the editorial board of various academic journals. Dr. Aragon-Ching has chaired national meetings at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and has delivered esteemed presentations at the Society of Urologic Oncology, Best of ASCO, AUA, EAU, and the ASCO Annual meeting. She has also been previously named a “Top Doctor” by Washingtonian magazine and a “Best Doctor” by the Northern Virginia magazine.
- Associate Professor of Medical Education, University of Virginia
- American College of Physicians
- American Society of Clinical Oncology
- Top Doctors, Washingtonian, 2022
Research and Publications
View list of publications from Dr. Aragon-Ching's research
Study Finds New Therapy Effective for Common, Advanced Bladder Cancer. May 2022.
Exploring Controversies Surrounding First-Line Therapy for Metastatic Urothelial Cancer. November 2021.
New Treatment Options Are Changing the Landscape for Prostate Cancer Patients. September 2019.
Treatment Innovation for Patients with Prostate, Bladder and Kidney Cancers. March 2018.
Do You Know the Warning Signs of Bladder Cancer? May 2017.
Prostate Cancer Is the Second Most Common Cancer in American Men. January 2017.
From Research to Results: Advances in Genitourinary Cancer Treatment. September 2015.
Medical EducationUniversity of Santo Tomas Hospital 1997
Training Specialty: Internal Medicine
5/1/1997 - 4/30/1998
Training Specialty: Internal Medicine
6/23/2000 - 6/30/2004
Training Specialty: Hematology/Oncology
7/1/2004 - 6/30/2008
About Patient Comments
The Patient Rating score is an average of all responses to physician related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.